Do analysts rate ASLN or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ALZN or ASLN?

Alzamend Neuro presently has a consensus target price of $28.00, indicating a potential upside of 1,966.42%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, equities analysts clearly believe Alzamend Neuro is more favorable than ASLAN Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ALZN or ASLN more profitable?

Alzamend Neuro's return on equity of -177.52% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% ASLAN Pharmaceuticals N/A -8,454.87% -121.60%

Do analysts prefer FLGC or ASLN?

Flora Growth currently has a consensus price target of $30.00, indicating a potential upside of 743.88%. Given Flora Growth's stronger consensus rating and higher possible upside, equities research analysts plainly believe Flora Growth is more favorable than ASLAN Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate DRMA or ASLN?

Dermata Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 736.82%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Dermata Therapeutics is more favorable than ASLAN Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is DRMA or ASLN more profitable?

Dermata Therapeutics' return on equity of -127.91% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -127.91% -105.05% ASLAN Pharmaceuticals N/A -8,454.87% -121.60%

Do analysts recommend ASLN or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASLN or GNPX more profitable?

Genprex's return on equity of -247.32% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Genprex N/A -247.32% -176.73%

Does the media favor ASLN or GNPX?

In the previous week, Genprex had 3 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 4 mentions for Genprex and 1 mentions for ASLAN Pharmaceuticals. Genprex's average media sentiment score of 0.79 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Genprex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ASLAN Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genprex 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ASLAN Pharmaceuticals (ASLN) Competitors

$0.60 0.00 (0.00%)

As of 06/24/2026

Compare

ASLN vs. INM, ALZN, FLGC, DRMA, and GNPX

Should you buy ASLAN Pharmaceuticals stock or one of its competitors? MarketBeat compares ASLAN Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ASLAN Pharmaceuticals include InMed Pharmaceuticals (INM), Alzamend Neuro (ALZN), Flora Growth (FLGC), Dermata Therapeutics (DRMA), and Genprex (GNPX). These companies are all part of the "pharmaceutical products" industry.

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

In the previous week, ASLAN Pharmaceuticals had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 1 mentions for ASLAN Pharmaceuticals and 0 mentions for InMed Pharmaceuticals. ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled InMed Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
InMed Pharmaceuticals	Neutral

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

InMed Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
InMed Pharmaceuticals	$4.94M	1.02	-$8.16M	-$2.89	N/A

ASLAN Pharmaceuticals has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

Summary

ASLAN Pharmaceuticals beats InMed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Alzamend Neuro?

Alzamend Neuro (NASDAQ:ALZN) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Alzamend Neuro has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Alzamend Neuro is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

Alzamend Neuro has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Alzamend Neuro's return on equity of -177.52% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

In the previous week, ASLAN Pharmaceuticals had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 1 mentions for ASLAN Pharmaceuticals and 0 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Alzamend Neuro	Neutral
ASLAN Pharmaceuticals	Neutral

Alzamend Neuro presently has a consensus target price of $28.00, indicating a potential upside of 1,966.42%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, equities analysts clearly believe Alzamend Neuro is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

ASLAN Pharmaceuticals beats Alzamend Neuro on 7 of the 13 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Flora Growth?

Flora Growth (NASDAQ:FLGC) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Flora Growth has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

36.0% of Flora Growth shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 2.3% of Flora Growth shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Flora Growth has higher revenue and earnings than ASLAN Pharmaceuticals. Flora Growth is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.06	-$15.91M	-$32.49	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

Flora Growth currently has a consensus price target of $30.00, indicating a potential upside of 743.88%. Given Flora Growth's stronger consensus rating and higher possible upside, equities research analysts plainly believe Flora Growth is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ASLAN Pharmaceuticals has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

In the previous week, ASLAN Pharmaceuticals had 1 more articles in the media than Flora Growth. MarketBeat recorded 1 mentions for ASLAN Pharmaceuticals and 0 mentions for Flora Growth. Flora Growth's average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Flora Growth	Neutral
ASLAN Pharmaceuticals	Neutral

Summary

Flora Growth beats ASLAN Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Dermata Therapeutics?

Dermata Therapeutics (NASDAQ:DRMA) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, ASLAN Pharmaceuticals had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 1 mentions for ASLAN Pharmaceuticals and 0 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
ASLAN Pharmaceuticals	Neutral

Dermata Therapeutics' return on equity of -127.91% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

Dermata Therapeutics has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Dermata Therapeutics is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Dermata Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 736.82%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Dermata Therapeutics is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dermata Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Summary

Dermata Therapeutics beats ASLAN Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Genprex?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Genprex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genprex's return on equity of -247.32% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Genprex	N/A	-247.32%	-176.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genprex has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Genprex is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Genprex has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market.

In the previous week, Genprex had 3 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 4 mentions for Genprex and 1 mentions for ASLAN Pharmaceuticals. Genprex's average media sentiment score of 0.79 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ASLAN Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genprex	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ASLAN Pharmaceuticals and Genprex tied by winning 6 of the 12 factors compared between the two stocks.

Get ASLAN Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASLN vs. The Competition

Export

Metric	ASLAN Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.23M	$953.36M	$6.66B	$12.19B
Dividend Yield	N/A	4.84%	2.68%	5.89%
P/E Ratio	-0.03	1.49	25.35	24.07
Price / Sales	0.10	118.21	588.85	125.28
Price / Cash	N/A	20.06	45.29	53.76
Price / Book	-0.09	7.89	10.56	6.37
Net Income	-$44.22M	-$4.05M	$3.56B	$337.11M
7 Day Performance	N/A	-0.36%	1.00%	-0.93%
1 Month Performance	N/A	-0.02%	0.80%	0.65%
1 Year Performance	N/A	45.64%	31.01%	29.50%

ASLAN Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASLN ASLAN Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$1.23M	$12M	N/A	30	News Coverage
INM InMed Pharmaceuticals	1.0313 of 5 stars	$1.49 +0.7%	N/A	-59.9%	$4.90M	$4.94M	N/A	10	Positive News
ALZN Alzamend Neuro	3.3996 of 5 stars	$1.25 -2.3%	$28.00 +2,140.0%	-53.2%	$4.87M	N/A	N/A	4	Gap Down
FLGC Flora Growth	N/A	$4.64 -5.6%	$30.00 +546.6%	-84.5%	$4.85M	$57.61M	N/A	280
DRMA Dermata Therapeutics	2.9409 of 5 stars	$1.33 +11.8%	$10.00 +651.9%	-80.8%	$4.79M	N/A	N/A	8	Analyst Upgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASLN) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. INM, ALZN, FLGC, DRMA, and GNPX

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

Summary

How does ASLAN Pharmaceuticals compare to Alzamend Neuro?

Summary

How does ASLAN Pharmaceuticals compare to Flora Growth?

Summary

How does ASLAN Pharmaceuticals compare to Dermata Therapeutics?

Summary

How does ASLAN Pharmaceuticals compare to Genprex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. INM, ALZN, FLGC, DRMA, and GNPX

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

Does the media prefer ASLN or INM?

Which has more volatility & risk, ASLN or INM?

Do analysts rate ASLN or INM?

Do insiders & institutionals have more ownership in ASLN or INM?

Which has better earnings and valuation, ASLN or INM?

Is ASLN or INM more profitable?

Summary

How does ASLAN Pharmaceuticals compare to Alzamend Neuro?

Which has better earnings & valuation, ALZN or ASLN?

Which has more risk and volatility, ALZN or ASLN?

Is ALZN or ASLN more profitable?

Does the media favor ALZN or ASLN?

Do analysts rate ALZN or ASLN?

Do institutionals and insiders hold more shares of ALZN or ASLN?

Summary

How does ASLAN Pharmaceuticals compare to Flora Growth?

Which has more volatility & risk, FLGC or ASLN?

Do insiders and institutionals hold more shares of FLGC or ASLN?

Which has preferable valuation & earnings, FLGC or ASLN?

Do analysts prefer FLGC or ASLN?

Is FLGC or ASLN more profitable?

Does the media favor FLGC or ASLN?

Summary

How does ASLAN Pharmaceuticals compare to Dermata Therapeutics?

Does the media prefer DRMA or ASLN?

Is DRMA or ASLN more profitable?

Which has better earnings & valuation, DRMA or ASLN?

Do institutionals & insiders hold more shares of DRMA or ASLN?

Do analysts rate DRMA or ASLN?

Which has more volatility & risk, DRMA or ASLN?

Summary

How does ASLAN Pharmaceuticals compare to Genprex?

Do institutionals and insiders hold more shares of ASLN or GNPX?

Is ASLN or GNPX more profitable?

Do analysts recommend ASLN or GNPX?

Which has stronger valuation and earnings, ASLN or GNPX?

Which has more volatility & risk, ASLN or GNPX?

Does the media favor ASLN or GNPX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools